SE0101082D0 - Novel use - Google Patents

Novel use

Info

Publication number
SE0101082D0
SE0101082D0 SE0101082A SE0101082A SE0101082D0 SE 0101082 D0 SE0101082 D0 SE 0101082D0 SE 0101082 A SE0101082 A SE 0101082A SE 0101082 A SE0101082 A SE 0101082A SE 0101082 D0 SE0101082 D0 SE 0101082D0
Authority
SE
Sweden
Prior art keywords
novel use
prophylaxis
pain
compounds
useful
Prior art date
Application number
SE0101082A
Other languages
English (en)
Swedish (sv)
Inventor
Sverker Hanson
Gunnar Nordvall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101082A priority Critical patent/SE0101082D0/xx
Publication of SE0101082D0 publication Critical patent/SE0101082D0/xx
Priority to US10/472,992 priority patent/US7067657B2/en
Priority to AU2002245005A priority patent/AU2002245005A1/en
Priority to EP02713341A priority patent/EP1377590B1/de
Priority to JP2002576248A priority patent/JP2004524351A/ja
Priority to PCT/SE2002/000599 priority patent/WO2002076990A1/en
Priority to AT02713341T priority patent/ATE370147T1/de
Priority to DE60221813T priority patent/DE60221813T2/de
Priority to ES02713341T priority patent/ES2290277T3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0101082A 2001-03-27 2001-03-27 Novel use SE0101082D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0101082A SE0101082D0 (sv) 2001-03-27 2001-03-27 Novel use
US10/472,992 US7067657B2 (en) 2001-03-27 2002-03-26 Thiazolopyrimidine derivatives and use thereof as antagonists of the CX3 CR1 receptor
AU2002245005A AU2002245005A1 (en) 2001-03-27 2002-03-26 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
EP02713341A EP1377590B1 (de) 2001-03-27 2002-03-26 Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
JP2002576248A JP2004524351A (ja) 2001-03-27 2002-03-26 新規な使用
PCT/SE2002/000599 WO2002076990A1 (en) 2001-03-27 2002-03-26 Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
AT02713341T ATE370147T1 (de) 2001-03-27 2002-03-26 Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
DE60221813T DE60221813T2 (de) 2001-03-27 2002-03-26 Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
ES02713341T ES2290277T3 (es) 2001-03-27 2002-03-26 Derivados de tiazolopirimidina y su uso como antagonistas del receptor cx3cr1.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101082A SE0101082D0 (sv) 2001-03-27 2001-03-27 Novel use

Publications (1)

Publication Number Publication Date
SE0101082D0 true SE0101082D0 (sv) 2001-03-27

Family

ID=20283552

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101082A SE0101082D0 (sv) 2001-03-27 2001-03-27 Novel use

Country Status (9)

Country Link
US (1) US7067657B2 (de)
EP (1) EP1377590B1 (de)
JP (1) JP2004524351A (de)
AT (1) ATE370147T1 (de)
AU (1) AU2002245005A1 (de)
DE (1) DE60221813T2 (de)
ES (1) ES2290277T3 (de)
SE (1) SE0101082D0 (de)
WO (1) WO2002076990A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313632D0 (en) * 2003-06-12 2003-07-16 Neuro Targets Ltd Chemokine receptors
EP1520586A1 (de) * 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibierung von Fractalkin oder von dessen Rezeptor zur Behandlung von atopishen Allergien
KR20060120014A (ko) * 2003-10-07 2006-11-24 아스트라제네카 아베 케모킨, 특히 ｃｘ3ｃｒ1 수용체 길항제로서 유용한 신규한2-치환된 4-아미노-티아졸로[4,5-ｄ]피리미딘
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) * 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
US20100215663A1 (en) * 2006-02-15 2010-08-26 Northwestern University Methods and compositions for regulation of neurological conditions
AU2007300749B2 (en) 2006-09-29 2011-08-25 Astrazeneca Ab Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3H)-amine derivatives and their use in therapy
TW200820973A (en) * 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
EP2913060A1 (de) 2014-02-28 2015-09-02 Universite De Nice Sophia-Antipolis Hemmung der Fraktalkin-Rezeptorinteraktion zur Behandlung von atopischer Dermatitis
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines

Also Published As

Publication number Publication date
AU2002245005A1 (en) 2002-10-08
WO2002076990A1 (en) 2002-10-03
WO2002076990A8 (en) 2002-11-14
EP1377590A1 (de) 2004-01-07
ES2290277T3 (es) 2008-02-16
DE60221813D1 (de) 2007-09-27
JP2004524351A (ja) 2004-08-12
US7067657B2 (en) 2006-06-27
ATE370147T1 (de) 2007-09-15
EP1377590B1 (de) 2007-08-15
US20040106628A1 (en) 2004-06-03
DE60221813T2 (de) 2008-05-08

Similar Documents

Publication Publication Date Title
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
BR0109703A (pt) Derivados de piperazina
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
GB0225475D0 (en) Therapeutic agents
GB0318447D0 (en) Therapeutic agents
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DK1379246T3 (da) Nocieptin-analoger
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
IL173377A0 (en) Compounds for the treatment of metabolic disorders
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
SE0101082D0 (sv) Novel use
IL172290A0 (en) Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
MXPA04003544A (es) Benzotriazepinas como ligandos del receptor de gastrina y colecistocinina.
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
SE0002739D0 (sv) New use
SE0200198D0 (sv) New use
SE0004827D0 (sv) Therapeutic compounds
BR0207307A (pt) Inibidores de glyt-1
AU2003216965A1 (en) Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases